Glucocorticosteroid Therapy on Drug-induced Liver Injury: a Prospective Non-randomized Concurrent Control Trial

Launched by LI YANG · Sep 16, 2020

Keywords

ClinConnect Summary

This clinical trial is studying the safety and effectiveness of a medication called glucocorticosteroids for treating drug-induced liver injury (DILI). DILI can happen when certain medications cause damage to the liver. The researchers want to see if glucocorticosteroids can help patients recover from this condition.

To be eligible for the trial, participants need to have a confirmed diagnosis of DILI and meet specific lab test results indicating the severity of their liver injury. They should be between the ages of 65 and 75 and cannot have had liver issues for more than six months or have other liver diseases. Those who join the study will receive glucocorticosteroids and will be monitored for how well it works and any side effects. This trial is currently recruiting, and both men and women can participate.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Clinical diagnosis of DILI
• • 2. RUCAM score≥6 and with liver histology
• 3. Meet any of the following conditions:
• • 1. TBIL ≥ 10 fold ULN ;
• • 2. TBIL ≥ 5 fold ULN and serum AST or ALT ≥ 20 fold ULN
• Exclusion Criteria:
• • 1. An chronic onset (≥6 months)
• • 2. Other liver diseases, such as autoimmune liver diseases, viral hepatitis, etc
• • 3. with contraindications of glucocorticoid